Sibrotuzumab ELISA Kit

Sibrotuzumab ELISA Kit is a quantitative ELISA kit for detection of Sibrotuzumab.

Sibrotuzumab (also known as BIBH 1) is a humanized monoclonal antibody (mAb) which has the high affinity to bind to fibroblast activation protein (FAP), which is highly expressed by stroma cells of tumors. In addition, it was intended and developed by Boehringer Ingelheim Pharma KG for the treatment of cancer. Firstly, this drug was designed to fight against various malignancies, such as colorectal, non-small cell lung, breast, as well as head and neck cancer. However, it is disappointing that in 2003 it failed a phase II clinical trial for metastatic colorectal cancer. At present, there is no relevant clinically approved information disclosure.

Target	Sibrotuzumab
Reactivity	Human
Tested Applications	ELISA
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Storage	Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.
Validity	The validity for this kit is 6 months.
Stability	The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.
Test Range	0.31 μg/ml - 5 μg/ml
Standard Form	Lyophilized
Detection Method	Colorimetric
Assay Type	Competitive
Assay Data	Quantitative
Sample Type	Serum and plasma.
CAS Number	216669-97-5
Availability	Shipped within 10-20 working days.
Note	This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Research Articles on Sibrotuzumab

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue